Statistical design considerations for pilot studies transitioning therapies from the bench to the bedside

被引:30
|
作者
Carter R.E. [1 ]
Woolson R.F. [1 ]
机构
[1] Dept. Biostatist. Bioinfo./Epidemiol, Medical University of South Carolina, Charleston, SC 29425
关键词
Hearing Loss; Translational Research; Transition Therapy; Augmentative Therapy; Initial Sample Size;
D O I
10.1186/1479-5876-2-37
中图分类号
学科分类号
摘要
Pilot studies are often used to transition therapies developed using animal models to a clinical setting. Frequently, the focus of such trials is on estimating the safety in terms of the occurrence of certain adverse events. With relatively small sample sizes, the probability of observing even relatively common events is low; however, inference on the true underlying event rate is still necessary even when no events of interest are observed. The exact upper limit to the event rate is derived and illustrated graphically. In addition, the simple algebraic expression for the confidence bound is seen to be useful in the context of planning studies. © 2004 Carter and Woolson; licensee BioMed Central Ltd.
引用
收藏
页数:3
相关论文
共 50 条
  • [1] CDG Therapies: From Bench to Bedside
    Brasil, Sandra
    Pascoal, Carlota
    Francisco, Rita
    Marques-da-Silva, Dorinda
    Andreotti, Giuseppina
    Videira, Paula A.
    Morava, Eva
    Jaeken, Jaak
    Ferreira, Vanessa dos Reis
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (05)
  • [2] From the bedside back to the bench: The role of preclinical studies in understanding clinical therapies
    Marshall, John C.
    CRITICAL CARE MEDICINE, 2010, 38 (01) : 329 - 330
  • [3] Trust in standards: Transitioning clinical exome sequencing from bench to bedside
    Timmermans, Stefan
    SOCIAL STUDIES OF SCIENCE, 2015, 45 (01) : 77 - 99
  • [4] Keratoconus: Ocular surface considerations, from bench to bedside
    Doroodgar, Farideh
    Niazi, Sana
    ACTA OPHTHALMOLOGICA, 2024, 102
  • [5] Idealized PPARγ-Based Therapies: Lessons from Bench and Bedside
    Amato, Angelica Amorim
    Rocha Neves, Francisco de Assis
    PPAR RESEARCH, 2012, 2012
  • [6] Stem cell therapies for retinal diseases: from bench to bedside
    Shen, Yuening
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2020, 98 (10): : 1347 - 1368
  • [7] Anti-Diabetic Therapies and Cancer: From Bench to Bedside
    Kounatidis, Dimitris
    Vallianou, Natalia G.
    Karampela, Irene
    Rebelos, Eleni
    Kouveletsou, Marina
    Dalopoulos, Vasileios
    Koufopoulos, Petros
    Diakoumopoulou, Evanthia
    Tentolouris, Nikolaos
    Dalamaga, Maria
    BIOMOLECULES, 2024, 14 (11)
  • [8] Emerging therapies for Parkinson's disease: From bench to bedside
    Tarazi, F. I.
    Sahli, Z. T.
    Wolny, M.
    Mousa, S. A.
    PHARMACOLOGY & THERAPEUTICS, 2014, 144 (02) : 123 - 133
  • [9] New therapies for inflammatory bowel disease: from the bench to the bedside
    Danese, Silvio
    GUT, 2012, 61 (06) : 918 - 932
  • [10] Fibrosis regression and innovative antifibrotic therapies: from bench to bedside
    Berries, M. -L.
    Zaldivar, M. M.
    Trautwein, C.
    Wasmuth, H. E.
    LIVER CIRRHOSIS: FROM PATHOPHYSIOLOGY TO DISEASE MANAGEMENT, 2008, 162 : 173 - 180